Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601435 | 0.94 | FABP5 (0.42) | FABP5FABP7EPHX2KMT2AGRM2 | |
| SCHEMBL4601160 | 0.93 | FABP5 (0.39) | FABP5FABP7EPHX2KMT2AGRM2 | |
| SCHEMBL4600307 | 0.92 | FABP5 (0.39) | FABP5FABP7EPHX2KMT2AGRM2 | |
| SCHEMBL4600355 | 0.91 | EPHX2 (0.38) | FABP5FABP7EPHX2KMT2AGRM2 | |
| SCHEMBL4601923 | 0.90 | FABP5 (0.40) | FABP5FABP7EPHX2GRM2 | |
| SCHEMBL27596048 | 0.90 | EPHX2 (0.38) | FABP5FABP7EPHX2KMT2AGRM2 | |
| SCHEMBL27596047 | 0.86 | FABP5 (0.39) | FABP5FABP7EPHX2KMT2AGRM2 | |
| SCHEMBL4601214 | 0.86 | FABP5 (0.38) | FABP5FABP7EPHX2KMT2AGRM2 | |
| SCHEMBL2190862 | 0.81 | CASP1 (0.41) | FABP5FABP7EPHX2KMT2AGRM2 | |
| SCHEMBL28864147 | 0.78 | EPHX2 (0.44) | FABP5FABP7EPHX2KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100491396-C | Selective cyclic peptides | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | CN | disclosed |
| US-20080177036-A1 | Selective Linear Peptides with Melanocortin-4 Receptor (MC4-R) Agonist Activity | CHEN LI | 2008-07-24 | — | — | US | disclosed |
| EP-1272516-B1 | SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-04-23 | — | — | EP | disclosed |
| EP-1315750-B1 | CYCLIC PEPTIDES HAVING MELANOCORTIN-4 RECEPTOR AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2007-02-14 | — | — | EP | disclosed |
| US-7045591-B2 | Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity | HOFFMANN-LA ROCHE INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050239711-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | CHEN LI | 2005-10-27 | — | — | US | disclosed |
| US-20030229200-A1 | Selective linear peptides with melanocor tin-4 receptor (MC4-R) agonist activity | CHEN LI (US) | 2003-12-11 | — | — | US | disclosed |
| CN-1451017-A | Selective cyclic peptides | HOFFMANN LA ROCHE (CH) | 2003-10-22 | — | — | CN | disclosed |
| US-6600015-B2 | Treatment or prevention of obesity. | HOFFMANN-LA ROCHE INC. | 2003-07-29 | — | — | US | disclosed |
| US-20020143141-A1 | Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity | CHEN LI (US) | 2002-10-03 | — | — | US | disclosed |
| US-20010056179-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | HOFFMANN-LA ROCHE INC. | 2001-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177036-A1 | Selective Linear Peptides with Melanocortin-4 Receptor (MC4-R) Agonist Activity | MC4R, MC3R, MC1R | FABP5 1678/4885FABP7 537/4885EPHX2 4214/4885 |
| US-20020143141-A1 | Selective cyclic peptides with melanocortin-4 receptor (MC4-R) agonist activity | MC4R, MC3R, MC1R | FABP5 2387/4885FABP7 795/4885EPHX2 3954/4885 |
| US-20050239711-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | MC4R, MC3R, MC1R | FABP5 1678/4885FABP7 537/4885EPHX2 4214/4885 |
| US-20030229200-A1 | Selective linear peptides with melanocor tin-4 receptor (MC4-R) agonist activity | MC4R, MC1R, MC3R | FABP5 2060/4885FABP7 747/4885EPHX2 4476/4885 |
| US-20010056179-A1 | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity | MC4R, MC3R, MC1R | FABP5 1851/4885FABP7 533/4885EPHX2 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.